Logo image of SONN

SONNET BIOTHERAPEUTICS HOLDI (SONN) Stock Fundamental Analysis

USA - NASDAQ:SONN - US83548R4020 - Common Stock

4.89 USD
-0.46 (-8.6%)
Last: 11/18/2025, 8:00:03 PM
4.861 USD
-0.03 (-0.59%)
After Hours: 11/18/2025, 8:00:03 PM
Fundamental Rating

0

Overall SONN gets a fundamental rating of 0 out of 10. We evaluated SONN against 533 industry peers in the Biotechnology industry. SONN has a bad profitability rating. Also its financial health evaluation is rather negative. SONN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SONN has reported negative net income.
In the past year SONN has reported a negative cash flow from operations.
In the past 5 years SONN always reported negative net income.
In the past 5 years SONN always reported negative operating cash flow.
SONN Yearly Net Income VS EBIT VS OCF VS FCFSONN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

SONN has a Return On Assets of -659.57%. This is amonst the worse of the industry: SONN underperforms 97.37% of its industry peers.
Industry RankSector Rank
ROA -659.57%
ROE N/A
ROIC N/A
ROA(3y)-375.01%
ROA(5y)-253.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SONN Yearly ROA, ROE, ROICSONN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K 10K 15K

1.3 Margins

SONN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SONN Yearly Profit, Operating, Gross MarginsSONN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

0

2. Health

2.1 Basic Checks

SONN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SONN has more shares outstanding
SONN has more shares outstanding than it did 5 years ago.
SONN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SONN Yearly Shares OutstandingSONN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K
SONN Yearly Total Debt VS Total AssetsSONN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -107.26, we must say that SONN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SONN (-107.26) is worse than 96.25% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -107.26
ROIC/WACCN/A
WACC8.77%
SONN Yearly LT Debt VS Equity VS FCFSONN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 0.26 indicates that SONN may have some problems paying its short term obligations.
The Current ratio of SONN (0.26) is worse than 94.75% of its industry peers.
A Quick Ratio of 0.26 indicates that SONN may have some problems paying its short term obligations.
SONN has a worse Quick ratio (0.26) than 94.56% of its industry peers.
Industry RankSector Rank
Current Ratio 0.26
Quick Ratio 0.26
SONN Yearly Current Assets VS Current LiabilitesSONN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

SONN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.17%, which is quite impressive.
The Revenue has grown by 1688.91% in the past year. This is a very strong growth!
SONN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -77.28% yearly.
EPS 1Y (TTM)70.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.04%
Revenue 1Y (TTM)1688.91%
Revenue growth 3Y-66.16%
Revenue growth 5Y-77.28%
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y68.91%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SONN Yearly Revenue VS EstimatesSONN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2028 2029 2030 2031 20M 40M 60M 80M
SONN Yearly EPS VS EstimatesSONN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2020 2021 2022 2023 2024 2025 -500 -1K -1.5K -2K -2.5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SONN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SONN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SONN Price Earnings VS Forward Price EarningsSONN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SONN Per share dataSONN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SONN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SONNET BIOTHERAPEUTICS HOLDI

NASDAQ:SONN (11/18/2025, 8:00:03 PM)

After market: 4.861 -0.03 (-0.59%)

4.89

-0.46 (-8.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)12-15 2025-12-15/amc
Inst Owners5.97%
Inst Owner Change13313.2%
Ins Owners0.59%
Ins Owner Change26.82%
Market Cap33.40M
Revenue(TTM)1.00M
Net Income(TTM)-13.56M
Analysts82.86
Price Target20.4 (317.18%)
Short Float %38.73%
Short Ratio2.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-42.46%
Min EPS beat(2)-90.08%
Max EPS beat(2)5.16%
EPS beat(4)2
Avg EPS beat(4)-15.74%
Min EPS beat(4)-90.08%
Max EPS beat(4)31.98%
EPS beat(8)5
Avg EPS beat(8)1.79%
EPS beat(12)8
Avg EPS beat(12)10.51%
EPS beat(16)11
Avg EPS beat(16)11.95%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 33.4
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.23
EYN/A
EPS(NY)-3.53
Fwd EYN/A
FCF(TTM)-1.51
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS0.15
BVpS-0.45
TBVpS-0.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -659.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-375.01%
ROA(5y)-253.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.78%
Cap/Sales 1.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.26
Quick Ratio 0.26
Altman-Z -107.26
F-Score4
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)4176.73%
Cap/Depr(5y)2511.15%
Cap/Sales(3y)207.2%
Cap/Sales(5y)124.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.04%
EPS Next Y68.91%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1688.91%
Revenue growth 3Y-66.16%
Revenue growth 5Y-77.28%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-468%
EBIT Next 3Y-90.14%
EBIT Next 5Y-41.82%
FCF growth 1Y55.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.05%
OCF growth 3YN/A
OCF growth 5YN/A

SONNET BIOTHERAPEUTICS HOLDI / SONN FAQ

Can you provide the ChartMill fundamental rating for SONNET BIOTHERAPEUTICS HOLDI?

ChartMill assigns a fundamental rating of 0 / 10 to SONN.


Can you provide the valuation status for SONNET BIOTHERAPEUTICS HOLDI?

ChartMill assigns a valuation rating of 0 / 10 to SONNET BIOTHERAPEUTICS HOLDI (SONN). This can be considered as Overvalued.


How profitable is SONNET BIOTHERAPEUTICS HOLDI (SONN) stock?

SONNET BIOTHERAPEUTICS HOLDI (SONN) has a profitability rating of 0 / 10.


How financially healthy is SONNET BIOTHERAPEUTICS HOLDI?

The financial health rating of SONNET BIOTHERAPEUTICS HOLDI (SONN) is 0 / 10.